AlphAIAlphAI — Financial news for AI agents
investing.com$ACRV

Acrivon advances CDK11 inhibitor for AML, targets 2027 IND filing

Acrivon Therapeutics (ACRV) announced the advancement of ACR-7280, an oral CDK11 inhibitor, as its next development candidate. The company plans to file an IND application for the drug with the FDA in the first half of 2027. ACR-7280 showed complete tumor regression in AML xenograft models and potential in combination therapies. Acrivon's lead program, ACR-368, is in a Phase 2 trial for endometrial cancer.

Original reporting
investing.com
Published Oct 20, 2026, 12:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 12:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$ACRV
Bullish
high confidence
Mentioned
$ACRV
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ACRVBullishMed
01

Why it matters

The IND filing plan signals progression toward clinical trials, a key value driver for early‑stage biotech.

02

Market read

New IND‑enabling program could lift ACRV on the back of novel AML therapy development.

03

What to watch

Funding requirements for the IND and competition from other CDK inhibitors.

Relevance 8/10Novelty 8/10Timing: today

Background

Acrivon is a clinical‑stage biopharma using its AP3 platform; its lead program ACR‑368 is in Phase 2 for endometrial cancer.

Company-level read

Ticker impact

$ACRVBullishHigh confidence
Context

Acrivon Therapeutics announced advancement of its CDK11 inhibitor ACR-7280 and plans an IND filing in early 2027, marking a new development milestone.

Expected impact

likely upward bias as market anticipates regulatory progress and potential future revenue.

Evidence & confidence

First disclosure of a new IND‑enabling program for a novel AML therapy; biotech stocks typically rally on such milestones.

Market effects

Sector

strengthens the AML therapeutic pipeline narrative and may boost peer biotech valuations.

Regional

U.S. biotech sector could see modest uplift.

Global

limited to biotech investors; no broad market effect.

Counterpoint

What could challenge this read

If preclinical results fail to translate, the stock could face disappointment.

Key entities

  • company
    Acrivon Therapeutics

    NASDAQ‑listed biotech developing CDK11 inhibitor ACR‑7280.

Read at source← All news

StoryAcrivon moves oral CDK11 inhibitor toward IND filing in early 2027

Also covered by

1 outlet

Related articles

$ACRVMedAI 8/10

Acrivon Therapeutics Highlights Phase 2-Ready ACR-525 and Preclinical EoE Programs

Acrivon Therapeutics presented its immunology and inflammation programs, including the Phase 2-ready ACR-525, a selective JAK1 inhibitor, and a preclinical PKCθ inhibitor program, at an R&D event. The company highlighted EoE's growing patient population and treatment gaps as rationale for ACR-525's development, citing favorable early clinical data and safety profile. The presentation is available on the company's investor website.

tradingview.com
$ACRVMedAI 8/10

Acrivon to present cancer drug trial data at November symposium

Acrivon Therapeutics (ACRV) will present Phase 1/2 trial data for ACR-2316 at a cancer symposium in November. The study showed clinical activity in endometrial and lung cancers, with one patient achieving complete response. The trial has progressed to dose expansion, including pancreatic cancer patients. ACRV uses its AP3 platform to predict patient responses.

investing.com
$ACRVMed

Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts

Acrivon Therapeutics, Inc. (ACRV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts ACR-368 Phase 2b prespecified interim analysis and data from all-comer serous endometrial cancer (EC) treatment arms on track for second half of 2026 ACR-2316 P

SEC EDGAR 8-K
$CAPRHighAI 8/10

CAPR Stock Rallies After-Hours As Capricor Reaffirms Deramiocel Confidence Ahead Of Nov. 22 Decision; Says Application In Final Review

Capricor (CAPR) stock rose after-hours as the company reaffirmed confidence in its Deramiocel treatment ahead of a November 22 decision. The HOPE-3 trial met its primary endpoint, showing a 1.1-point improvement in upper limb function. Capricor reported a Q3 net loss of $42.7 million and $198.5 million in cash reserves. Retail sentiment on StockTwits was extremely bullish, with mixed opinions on approval odds. CAPR stock is down 69% year-to-date.

finance.yahoo.com